Patients with large numbers of ACFare at increased risk for development of subsequent colon cancers [45–47], and it is plausible thatshort-term treatment with PPARγ agonists might result in a decrease in ACFsand a subsequent reduction in colon cancer risk. The gene discussed is PPARG; the disease is malignant colon neoplasm.